WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018026600) DISRUPTING FC RECEPTOR ENGAGEMENT ON MACROPHAGES ENHANCES EFFICACY OF ANTI-SIRPALPHA ANTIBODY THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/026600    International Application No.:    PCT/US2017/043935
Publication Date: 08.02.2018 International Filing Date: 26.07.2017
IPC:
A61K 39/395 (2006.01), A61K 39/00 (2006.01)
Applicants: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel Building 170, 3rd Floor, Main Quad P.O. Box 20386 Stanford, California 94305-2038 (US).
FORTY SEVEN, INC. [US/US]; 1490 O'Brien Drive, Suite A Menlo Park, California 94025 (US)
Inventors: LIU, Jie; (US).
RING, Aaron Michael; (US).
VOLKMER, Jens-Peter; (US).
WEISSMAN, Irving L.; (US)
Agent: SHERWOOD, Pamela J.; (US)
Priority Data:
62/370,422 03.08.2016 US
Title (EN) DISRUPTING FC RECEPTOR ENGAGEMENT ON MACROPHAGES ENHANCES EFFICACY OF ANTI-SIRPALPHA ANTIBODY THERAPY
(FR) L'INTERRUPTION DE L'ENGAGEMENT DU RÉCEPTEUR FC SUR LES MACROPHAGES AMÉLIORE L'EFFICACITÉ DE LA THÉRAPIE PAR ANTICORPS ANTI-SIRPALPHA
Abstract: front page image
(EN)Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.
(FR)L'invention concerne des anticorps anti-SIRPα, y compris des anticorps multi-spécifiques anti-SIRPα, ainsi que des compositions et des procédés associés. Les anticorps de l'invention se lient à la protéine SIRPα et peuvent bloquer les interactions entre la protéine CD47 présente sur une cellule et la protéine SIRPα présente sur une cellule phagocytaire. Les anticorps anti-SIRPα de la présente invention peuvent être utilisés dans différents procédés thérapeutiques. Des modes de réalisation de l'invention concernent des anticorps isolés et des dérivés et fragments de ceux-ci, des compositions pharmaceutiques contenant un ou plusieurs de ces anticorps anti-SIRPα; et des lignées cellulaires qui produisent ces anticorps. L'invention concerne également des séquences d'acides aminés d'anticorps anti-SIRPα donnés à titre d'exemple.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)